Quarterly report · Q3
7745.TEDINET S100SUG2
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥44.5bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥59.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥42.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥5.2bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥4.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥5.3bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.6bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.9bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥5.3bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.9bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥3.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥69.5bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥69.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥68.1bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.1bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥36.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥35.4bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥32.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥30.9bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥15.0bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥15.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥132.3 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.99 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.33 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.43 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥132.17 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥201.14 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥128.31 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 50.8% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥18.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥18.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥1.7bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥3.3bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥3.1bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥266m |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥107m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥7.1bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥7.1bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥427m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥5.7bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥3.7bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥1.9bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥292m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥6.3bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥288m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥6.1bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥306m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥452m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥452m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥36m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥11m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥358m |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥14.2bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥12.2bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥490m |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥12.4bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥3.9bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥8.6bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.1bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥7.8bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥7.8bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥23.6bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥19.5bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥854m |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥31.8bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥17.2bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥14.6bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥3.2bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥7.8bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥7.8bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.8bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥21.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥21.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.9bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.7bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.4bn |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥352m |
| jpcrp040300-q3r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥486m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1m |
| jpcrp040300-q3r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥31m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.3bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥451m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.4bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥328m |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥7.0bn |
| jpcrp040300-q3r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥242m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥730m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥729m |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥102m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥3m |
| jpcrp040300-q3r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥11.0bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2.9bn |
| jpcrp040300-q3r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥541m |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.1bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.0bn |
| jpcrp040300-q3r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.3bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.3bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥25.6bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥19.9bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥34.5bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.4bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥16.1bn |
| jpcrp040300-q3r_E02344-000Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 449
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes payable | CurrentQuarterInstant | 409000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 1398000000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 723000000 | JPY |
| Provision for product warranties | Prior1YearInstant | 212000000 | JPY |
| Provision for product warranties | CurrentQuarterInstant | 345000000 | JPY |
| Other cl | Prior1YearInstant | 6254000000 | JPY |
| Other cl | CurrentQuarterInstant | 6084000000 | JPY |
| Current liabilities | Prior1YearInstant | 31202000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 29421000000 | JPY |
| Long term loans payable | Prior1YearInstant | 3292000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 2293000000 | JPY |
| Provision for directors retirement benefits | Prior1YearInstant | － | JPY |
| Provision for directors retirement benefits | CurrentQuarterInstant | 119000000 | JPY |
| Provision for product warranties ncl | Prior1YearInstant | 54000000 | JPY |
| Provision for product warranties ncl | CurrentQuarterInstant | 95000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 1064000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 1068000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | Prior1YearInstant | 92000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | CurrentQuarterInstant | 86000000 | JPY |
| Other ncl | Prior1YearInstant | 1135000000 | JPY |
| Other ncl | CurrentQuarterInstant | 998000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 5640000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 4661000000 | JPY |
| Liabilities | Prior1YearInstant | 36843000000 | JPY |
| Liabilities | CurrentQuarterInstant | 34082000000 | JPY |
| Capital stock | Prior1YearInstant | 6388000000 | JPY |
| Capital stock | CurrentQuarterInstant | 6388000000 | JPY |
| Capital surplus | Prior1YearInstant | 8319000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 8319000000 | JPY |
| Retained earnings | Prior1YearInstant | 19142000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 21806000000 | JPY |
| Treasury stock | Prior1YearInstant | -172000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -162000000 | JPY |
| Shareholders equity | Prior1YearInstant | 33677000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 36351000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 31000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 36000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | -1250000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | -1101000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 43000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 7000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | -1175000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | -1056000000 | JPY |
| Non controlling interests | Prior1YearInstant | 72000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 82000000 | JPY |
| Net assets | Prior1YearInstant | 32574000000 | JPY |
| Net assets | CurrentQuarterInstant | 35377000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 69418000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 69460000000 | JPY |
| Net sales | Prior1YTDDuration | 42217000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |